Cincinnati · Montgomery · Edgewood, KY By appointment · Most insurance accepted
Contact
Request a Consultation

RegenLife Centers · Physician-led care

Sacroiliac Joint Pain

PRP and Prolotherapy for SI Joint Dysfunction

Published on October 8th, 2026

Caitlyn Benton
Written by
Caitlyn Benton
Dr. Zeeshan Tayeb
Reviewed and Approved by
Dr. Zeeshan Tayeb

Persistent symptoms often affect daily life before patients receive a clear diagnosis or lasting relief.

Sacroiliac joint dysfunction is estimated to account for 15–30% of all chronic low back pain cases, making it one of the most prevalent and most chronically undertreated sources of pain in clinical practice. At RegenLife Centers for Integrative Pain & Weight Management, the regenerative program applies PRP therapy and prolotherapy to sacroiliac joint dysfunction with the specific biological goal that distinguishes them from steroid injections, not suppressing the pain signal, but repairing the ligamentous structures that are generating it.

Close-up of a woman's hands gripping her painful back while outdoors.Close-up of a woman's hands gripping her painful back while outdoors.

Key Takeaways

  • Sacroiliac joint pain accounts for 15–30% of chronic low back pain and is the third most common cause of low back pain overall: yet it is frequently missed when clinical evaluation focuses exclusively on lumbar disc and facet pathology
  • Prolotherapy for SI joint dysfunction demonstrated positive outcomes in 76% of patients at the 3-month and 12-month marks, with dextrose injection producing longer-lasting relief than corticosteroid injection at comparable follow-up timepoints
  • PRP injection required an average of 1.6 treatments compared to 3.0 for prolotherapy in a direct comparison study, with both groups achieving major pain and function improvements by the 3-month mark: suggesting PRP delivers equivalent outcomes in fewer sessions
  • The biological mechanism of prolotherapy and PRP addresses the root cause of SI joint pain: ligamentous laxity and structural instability, rather than the downstream inflammatory signal that cortisone targets and that returns once the steroid effect dissipates

Sacroiliac Joint Dysfunction: The Low Back Pain Diagnosis Most Evaluations Miss

Doctor reviewing spinal X-ray film in a hospital settingDoctor reviewing spinal X-ray film in a hospital setting

The Anatomy and Mechanics of the SI Joint

The sacroiliac joints are among the largest joints in the body, bilateral articulations where the sacrum, the triangular base of the spine, meets the iliac bones of the pelvis. They are designed primarily for load transfer rather than motion: unlike the hip or knee, which require significant range of movement, the SI joints transmit the compressive force of the upper body to the lower extremities through a combination of bony interlocking and the strongest ligamentous complex in the body. The sacroiliac ligaments, posterior, anterior, and interosseous, do more than hold the joint together; they absorb and distribute the mechanical forces of every step, every rotation, and every load-bearing activity.

When those ligaments are overstretched, partially torn, or chronically inflamed, the joint becomes either hypermobile or hypomobile, too much movement producing instability and microtrauma, too little movement producing fixation and referred pain. Both patterns generate pain in anatomically predictable locations: the posterior superior iliac spine and the region just below it, the ipsilateral buttock, the posterior thigh, and in more severe cases, the groin, lateral hip, and lower extremity to the knee or ankle. The radiation pattern mimics lumbar disc herniation closely enough that without systematic examination and appropriate provocative testing, the SI joint is regularly attributed to a lumbar source that imaging then fails to confirm.

Why SI Joint Pain Goes Undiagnosed

The diagnostic challenge with sacroiliac joint dysfunction is structural: standard MRI protocols are optimized for lumbar disc, facet joint, and spinal cord pathology, and the SI joint, while visible, is not the focus of the acquisition sequence, the radiologist's report, or the referring clinician's differential. A lumbar MRI that shows no significant disc herniation or neural compression does not assess SI joint ligamentous integrity. It simply excludes the conditions it was designed to find.

Clinical diagnosis of SI joint dysfunction relies on provocation testing that identifies characteristic pain patterns reproducibly. The five-test clinical battery, Gaenslen test, thigh thrust, distraction (gapping) test, compression test, and sacral thrust, achieves sensitivity of 94% and specificity of 78% when three or more tests are positive. A diagnostic intra-articular block with local anesthetic, performed under fluoroscopic guidance, provides the confirmatory standard: if injecting the joint relieves the pain, the SI joint is the source. The combination of a positive provocation battery and confirmed response to diagnostic block is the clinical foundation on which interventional and regenerative treatment planning proceeds.

The Patient Population Most Affected

SI joint dysfunction is not randomly distributed. Women are disproportionately affected, primarily because pregnancy and childbirth subject the SI joint to the combination of hormonal ligamentous laxity, produced by relaxin, and the mechanical stress of carrying and delivering a fetus. The joint that relaxed hormonally to accommodate childbirth does not always return to its pre-pregnancy mechanical stability, leaving postpartum patients with a ligamentous laxity that generates ongoing pain. Patients who have undergone prior lumbar spinal fusion are a second high-risk group: fusing segments above the SI joint concentrates mechanical force on the joint itself, accelerating degeneration and ligamentous stress. Athletes who sustain pelvic or lower back trauma, and individuals involved in motor vehicle accidents with sudden rotational force on the pelvis, round out the typical presenting population.


Why Corticosteroid Injection Fails Most SI Joint Patients Durably

Standard interventional treatment for SI joint pain follows the same pattern as standard care for most joint pain: intra-articular corticosteroid injection to suppress inflammation, followed by physical therapy. For patients whose SI joint pain has a significant inflammatory component, acute sacroiliitis in ankylosing spondylitis, for example, steroid injection provides meaningful relief. But for the much larger population whose pain derives from ligamentous laxity, chronic mechanical instability, and the progressive structural deterioration that follows years of abnormal joint mechanics, cortisone addresses the wrong pathophysiology.

The mechanism of corticosteroid injection is anti-inflammatory: it suppresses the immune signaling that produces local inflammation and, in doing so, reduces the pain signal generated by inflamed tissue. What it does not do is restore ligamentous tensile strength, reduce joint hypermobility, or initiate the collagen repair process that stabilizes the SI joint. In the connective tissue that actually holds the SI joint together, the interosseous and posterior sacroiliac ligaments, repeated steroid injection produces catabolic effects, progressively weakening the collagen matrix it was never designed to repair. The patient achieves weeks to months of partial relief, the ligamentous laxity continues or worsens, and the pain returns to baseline with the next round of activity. The cycle continues.

This is precisely the gap that PRP therapy and prolotherapy fill, and the biological reason that both have attracted serious clinical investigation as SI joint treatments.


Prolotherapy for Sacroiliac Joint Dysfunction: Rebuilding the Ligament

The Mechanism: Controlled Repair Through Targeted Inflammation

Prolotherapy for SI joint dysfunction involves the injection of a concentrated dextrose (glucose) solution, typically 12.5–25% concentration, into and around the sacroiliac ligament complex, specifically the posterior sacroiliac and interosseous ligaments that are most vulnerable to stretch injury and chronic laxity. The dextrose solution triggers a precisely controlled local inflammatory response that recruits the same repair cells and growth factors the body uses to heal any connective tissue injury: fibroblasts, macrophages, and the platelet-derived growth factors that initiate collagen synthesis.

The result, over a series of treatments, is new collagen deposition and ligament tightening, mechanical stabilization of the joint at the structural level rather than suppression of the pain signal at the inflammatory level. For patients whose pain is driven by the abnormal joint motion that occurs when SI ligaments can no longer maintain appropriate joint mechanics, this structural repair addresses the source rather than the downstream consequence.

What the Clinical Evidence Shows

A study published in the British Journal of Sports Medicine found positive clinical outcomes in 76% of patients treated with prolotherapy for sacroiliac joint problems at the 3-month follow-up, a result that held at 12 months. Functional outcomes and pain scores both improved significantly, and the durability of relief exceeded that of comparable corticosteroid injection at equivalent timepoints. Level 1, 3, and 4 evidence across multiple study designs confirms that dextrose prolotherapy produces statistically significant pain relief and return of function for SI joint ligament injury.

The treatment protocol most consistently used in the research literature involves 3 injections at 6-week intervals into the dorsal interosseous ligament of the affected sacroiliac joint, a cadence designed to allow the initial inflammatory repair response from each session to progress before the next stimulus is applied. Patients with longer symptom duration, sacroiliac instability that has been generating pain for years rather than months, typically require the full treatment series, while those treated earlier in the course of their dysfunction may respond after two sessions. Diagnostic services that establish the degree of ligamentous laxity and inflammatory load help determine the appropriate protocol for each patient's specific presentation.

Who Responds Best to Prolotherapy

Clinical patterns in the prolotherapy literature suggest that the patients who achieve the most complete and durable outcomes are those whose pain is driven primarily by ligamentous laxity and joint instability rather than arthritic joint degeneration. Postpartum patients with SI joint hypermobility from pregnancy-related relaxin exposure, patients with chronic instability following trauma or whiplash, and athletes whose repetitive loading has produced progressive ligament overstretching represent the clearest clinical indications. Patients with advanced SI joint osteoarthritis, inflammatory arthropathies like ankylosing spondylitis, or pain primarily from nerve entrapment at the piriformis or sciatic notch typically have additional pathological contributors that prolotherapy alone does not fully address, though it may still contribute to a coordinated treatment program.


PRP Therapy for Sacroiliac Joint Pain: Concentrated Healing Biology

Close-up of a healthcare professional drawing blood for PRP preparation in a clinical settingClose-up of a healthcare professional drawing blood for PRP preparation in a clinical setting

How PRP Differs From Prolotherapy in the SI Joint

PRP therapy uses a different biological vehicle to achieve a similar therapeutic objective. The patient's own blood is drawn and centrifuged to isolate the platelet-rich fraction, concentrating platelets 3–8 times above baseline, and the resulting preparation is injected under ultrasound or fluoroscopic guidance into the sacroiliac joint and surrounding ligamentous structures. The concentrated platelet fraction delivers a payload of growth factors, platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), and insulin-like growth factor-1 (IGF-1), that directly stimulate the repair and regeneration of damaged connective tissue.

Where prolotherapy induces repair indirectly by triggering an inflammatory recruitment response, PRP delivers the biological signals of repair directly. The two approaches share the goal of ligamentous regeneration and structural stabilization, but PRP operates through a more concentrated and growth-factor-rich mechanism that appears to produce equivalent or superior outcomes in fewer treatment sessions.

The Comparative Evidence: PRP vs. Prolotherapy

A direct comparison study examining ultrasound-guided PRP injection against prolotherapy for sacroiliac joint mechanical dysfunction found outcomes that favor PRP on efficiency metrics while confirming both modalities as clinically effective. The PRP group required an average of 1.6 injections to achieve significant improvement in pain score and function, compared to 3.0 injections in the prolotherapy group, a 47% reduction in treatment burden. Both groups demonstrated major improvements by the 3-month mark, with outcomes plateauing through 12 months, suggesting that the repair achieved by either treatment is durable once completed.

The study populations were comparable at baseline, clinical examination scores of 7.7 for the PRP group and 7.2 for the prolotherapy group, with mean ages of 38.7 and 40.4 years respectively, and symptom duration of approximately 46–48 months in both groups, meaning all patients had chronic SI joint dysfunction that had failed physiotherapy before entering the study. PRP's additional practical advantage over dextrose prolotherapy in this population was the use of ultrasound guidance rather than CT guidance, eliminating the radiation exposure associated with CT-guided prolotherapy in younger patients.

A 2025 systematic review published in Current Pain and Headache Reports examined the full body of evidence on PRP and stem cell injections for sacroiliac joint pain, identifying 2 randomized controlled trials and 3 observational studies. Five of the seven studies reviewed demonstrated clinical effectiveness exceeding 50% in their primary outcome measures, and the authors concluded that "emerging clinical evidence supporting their use appears promising", acknowledging both the therapeutic signal and the need for additional high-quality studies to establish the strength of the recommendation.

Selecting Between PRP and Prolotherapy

The choice between PRP and prolotherapy for SI joint dysfunction in clinical practice involves several considerations: the degree and nature of tissue damage, the treatment trajectory preferred by the patient, and the specific structural pathology identified on evaluation. For patients with significant articular cartilage involvement alongside ligamentous laxity, PRP's more comprehensive growth factor payload may offer broader tissue repair coverage than dextrose prolotherapy alone. For patients whose presentation is primarily ligamentous instability without intra-articular pathology, the hypermobile SI joint without joint degeneration, prolotherapy remains a highly effective and well-characterized option at lower cost per session.

In practice, interventional pain procedures at RegenLife include both approaches, and the selection is guided by comprehensive evaluation that identifies the structural contributors to each patient's specific SI joint presentation rather than applying a uniform protocol across the population.


Physical Rehabilitation and the Role of Stabilization

Therapist assisting a patient during physical therapy rehabilitation sessionTherapist assisting a patient during physical therapy rehabilitation session

Why Regenerative Treatment Works Better With Rehabilitation

Prolotherapy and PRP create the biological conditions for ligamentous repair, but they do not, on their own, train the neuromuscular system to use the restored joint stability appropriately. A repaired SI ligament placed back into the same movement patterns and muscle recruitment deficits that contributed to its overstretching will be subjected to the same mechanical stresses that damaged it in the first place. The clinical objective, durable stabilization of the SI joint, requires both the structural repair that regenerative treatment provides and the functional stability that targeted rehabilitation produces.

The physical therapy and exercise therapy programs at RegenLife addressing SI joint dysfunction focus specifically on the muscle groups that provide dynamic stabilization to the pelvis: the gluteus medius and maximus, the hip external rotators, the deep stabilizing fibers of the lumbar multifidus, and the transverse abdominis. These muscles function as the active stabilization system for a joint whose passive stability, the ligaments, has been compromised. Building and coordinating these muscle groups after regenerative treatment converts the repaired structural environment into functional joint stability that patients can maintain through activity.

Chiropractic and Manual Therapy in SI Joint Dysfunction

The SI joint commonly develops regions of restricted mobility, areas of hypomobility, that coexist with the hypermobility produced by ligamentous laxity, as the joint compensates for instability in one region by stiffening in adjacent articulations. Chiropractic care addresses this pattern of restricted joint motion through targeted manipulation that restores normal segmental mechanics, reducing the referred pain and muscle guarding that segmental restriction generates.

Manual therapy in the context of SI joint dysfunction is most effective when applied after regenerative treatment has addressed the underlying structural instability, because manipulation of a hypermobile joint without first stabilizing it can exacerbate the laxity pattern. The sequencing, regenerative treatment to restore ligamentous integrity, followed by manual therapy to restore normal motion patterns, followed by rehabilitation to build dynamic stabilization, reflects the biological logic of the whole-system approach RegenLife applies to complex musculoskeletal presentations.


Hormonal and Systemic Factors in SI Joint Dysfunction

Pregnancy, Postpartum, and Hormonal Laxity

The largest single cause of SI joint hypermobility in women is the hormonal environment of pregnancy. Relaxin, produced by the corpus luteum and the placenta, increases ligamentous compliance throughout the pelvic girdle to accommodate the mechanical demands of fetal growth and the passage of delivery, a physiological process that, in a subset of patients, leaves the SI ligaments insufficiently tightened postpartum. Women who experience pelvic girdle pain during pregnancy that does not fully resolve after delivery are the presenting profile most clearly suited for prolotherapy, because their pain mechanism is ligamentous laxity, their structural anatomy is known, and their response to regenerative treatment that restores ligament tensile strength is consistently positive.

Estrogen deficiency in perimenopausal and postmenopausal women compounds this picture: estrogen is anabolic for connective tissue, and declining estrogen levels reduce the capacity for ligamentous repair and increase SI joint vulnerability to progressive laxity with age. Identifying and correcting this hormonal contributor through hormone therapy creates the biological environment in which regenerative treatment achieves its full structural repair effect, the same logic that applies to PRP for any connective tissue pathology in hormonally deficient patients.

Inflammatory Load and Systemic Contributors

In patients with elevated systemic inflammatory markers, high-sensitivity CRP, elevated IL-6, or metabolic inflammation from insulin resistance, the SI joint's local repair response is impaired by the same inflammatory environment that undermines healing throughout the body. ANS testing that identifies chronic sympathetic overactivation provides an objective measure of the neurological stress environment in which SI joint pain and regenerative treatment are operating, and patients with significant sympathetic dysregulation typically respond more slowly to regenerative injection until the autonomic environment is addressed alongside the structural pathology.

The comprehensive metabolic and hormonal assessment that diagnostic services at RegenLife provide, including inflammatory markers, fasting insulin, full thyroid panel, and sex hormone levels, identifies the systemic factors that determine how effectively each patient's biology responds to the tissue repair stimulus that PRP and prolotherapy provide.


Contact RegenLife Centers to schedule an evaluation or ask which service fits your needs.


Frequently Asked Questions

Find answers to common questions

Ready to Learn More?

To learn more and to find out if you might be a good candidate at RegenLife, schedule a consultation with our team today.

About the Author

Caitlyn Benton

Caitlyn Benton, Research Manager at RegenLife

As Research Manager, Caitlyn Benton oversees the strategic planning and execution of clinical research projects, ensuring all studies adhere to the highest regulatory and ethical standards. With expertise in protocol development and data monitoring, she coordinates multidisciplinary teams to ensure the integrity of our clinical research programs and the accuracy of the insights shared with our patients.

Reviewed and Approved by

Dr. Zeeshan Tayeb

Dr. Zeeshan Tayeb, Medical Director at RegenLife

Interventional Spine, Pain, and Sports Medicine Dr. Zeeshan Tayeb, MD is board-certified in Pain Medicine and Physical Medicine & Rehabilitation, with specialized fellowship training in interventional spine, pain, and sports medicine. He sees patients at Pain Specialists of Cincinnati/RegenLife in Cincinnati, Ohio. Dr. Tayeb's background in physical medicine and rehabilitation has provided the foundation for his comprehensive approach to treating the whole person. Dr. Tayeb has done extensive training and education in both functional and regenerative medicine and specializes in state-of-the-art treatments, including laser therapies, PRP and stem-cell injections, and nutritional and hormonal optimization.

Disclaimer:

As a service to our readers, RegenLife provides access to our library of archived content. Please note the date of last review or update on all articles.

No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Stay Updated With Our Latest News

Check back regularly for new articles and updates about pain management treatments, practice news, and health tips from our team of specialists.

Get In Touch

Same-week consults. Real follow-through.

Tell us what's going on. A coordinator will follow up during office hours to help book your visit.

Request a consultation

Choose the clinic that works for you.

Most new patients can be seen within the same week.

Cincinnati

3328 Westbourne Dr

Cincinnati, OH 45248

(513) 922-2204

Edgewood

162 Barnwood Dr

Edgewood, KY 41017

(859) 331-4159

Montgomery

9989 Montgomery Rd

Montgomery, OH 45242

(513) 922-2204

We accept most major insurance plans

Request